To investigate the correlation between hyperandrogenism (HA) and insulin resistance (IR) in women with polycystic ovary syndrome (PCOS) by measuring serum total testosterone (TT) using a liquid chromatography and tandem mass spectrometry assay (LC-MS/MS).
| INTRODUC TI ON
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy among young women, affecting 5%-10% of women of childbearing age.
1,2 Hyperandrogenism (HA) and insulin resistance (IR) are regarded as two essential physiopathological characteristics of PCOS. 3 A previous study reported a significant positive correlation between insulin and androgen levels in PCOS 4 and the intense debate on the causal relationship between HA and IR Lately, animal experiments suggest that IR may play a more important role in the pathogenesis and development of PCOS, and more recent studies implicate IR as one of the causes responsible for the occurrence and progress of HA. 5, 6 However, to the best of our knowledge, the strong correlation between IR and HA observed in animal experiments is not supported by the clinical evidence, and this observation is largely attributed to the inaccurate measurement of androgens 7 as demonstrated in the existing reports.
Recent recommendations by professional societies and experts have explicitly stated the importance and high accuracy of using liquid chromatography and tandem mass spectrometry (LC-MS/MS) to measure total testosterone (TT) levels in women. 8, 9 In a previous study, we found that the TT level measured by LC/MS-MS was more closely related to the modified Ferriman Gallwey (mFG) score (r = 0.642, P < 0.001) than the TT level measured by chemiluminescent immunoassay (CLIA) was. Therefore, we wondered whether a more accurate measurement of TT would lead to an elevated incidence of IR in PCOS women with HA and whether the correlation between TT and IR was previously underestimated in clinical practice owing to the less accurate method of TT measurement. In the present study, we re-evaluated the potential correlation between HA and IR by comparing a non-PCOS IR cohort and a control group, as well as by comparing the subgroups among PCOS patients, based on LC-MS/MS measurements of serum TT levels. 12 Patients with PCO or any other endocrine disorder were excluded.
| MATERIAL S AND ME THODS

| Study populations
| PCOS patients
| Control group
The control group consisted of women aged 18-44 years, who con- 
| Collection of clinical, biochemical, and metabolic data
Information concerning menstrual regularity, hirsutism, acne, androgenic alopecia, gynecologic and obstetric history, medications, and family history of related disorders were collected for all patients.
Physical examination was also conducted to obtain parameters such as blood pressure, body mass index (BMI, calculated as weight in kilograms divided by height in square meters), and waist-to-hip ratio.
The mFG system was used to evaluate terminal hair growth. Levels of pituitary hormone, ovarian and adrenal steroids, and thyroid-stimulating hormone were measured during the first five days of spontaneous menstrual cycles or at progestin-withdrawal bleeding. An OGTT using 75 g of glucose was performed after an overnight fast of at least 
| Statistical analyses
Relevant IR parameters, including IFG, IGT, hyperinsulinemia (HIN, fasting plasma insulin ≥11.87 mIU/L), 12 increased HOMA-IR, INS peak shift and acanthosis nigricans (AN), were used to differentiate the IR subgroup from the non-IR subgroup among PCOS patients.
TT level was adopted as an indicator to distinguish the biochemically high TT (HT) and normal TT (NT) subgroups, with the cut-off value set at 1.85 nmol/L for LC-MS/MS (determined by k-means cluster analysis from 198 healthy reproductive-age women with the same genetic background) and 2.39 nmol/L for CLIA measurements (determined by k-means cluster analysis from 450 well-characterized healthy controls with the same genetic background). Clinical HA was considered equivalent to hirsutism and was defined by an mFG score ≥5 based on our previous study.
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In the present study, data are presented as the means ± standard deviation (SD). The Kolmogorov-Smirnov test was used to examine the normal distribution. A t test or one-way analysis of variance 
| Ethical approvals
| Notably, there was an increased incidence of HA in the IR subgroup compared with the non-IR subgroup among the PCOS patients
In addition to the comparison between the IR cohort and control group of non-PCOS women, we also analyzed 332 PCOS patients by comparing IR and non-IR subgroups based on parameters including IFG, IGT, HIN, HOMA-IR, INS peak shift, and signs of AN.
The rates of HA determined by LC-MS/MS (TT ≥ 1.85 nmol/L) were significantly higher in the IR subgroup than in the non-IR subgroup when the IR subgroups were defined by HIN (80.97% vs 37.89%, P < 0.001), increased HOMA-IR (68.53% vs 38.52%, P < 0.001) and IFG (80.36% vs 51.45%, P < 0.001; Figure 2A ). In contrast, CLIAbased measurements failed to reveal a statistically significant difference in HA (TT ≥ 2.39 nmol/L) incidence between the subgroups with or without IR ( Figure 2B ).
In addition, when HA was identified by either a high mFG score (mFG ≥ 5) or an increased LC-MS/MS-based TT, the HA rate was also higher in the IR subgroup defined by HIN (91.55%
vs 52.63%, P < 0.001), increased HOMA-IR (81.22% vs 51.85%, P < 0.001), and IFG (85.71% vs 65.94%, P < 0.01) than in the non-IR subgroup ( Figure 2C ). Similar results were obtained for the rate of HA determined by a higher mFG score alone when the IR subgroup was differentiated from the non-IR subgroup by HIN and increased HOMA-IR (P < 0.001) or by IFG (P < 0.05; Figure 2D ).
| LC-MS/MS revealed a higher IR incidence in PCOS patients with HT than in those with NT
To compare the IR rate between the patients with HT identified by LC-MS/MS and those identified by CLIA, we divided the PCOS population into HT and non-HT subgroups using cut-off TT values of ≥1.85 nmol/L for LC-MS/MS (HT-LCMS and NT-LCMS subgroups)
and ≥2.39 nmol/L for CLIA (HT-CLIA and NT-CLIA subgroups). The baseline characteristics of the subgroups with and without increased TT levels are demonstrated in Table S1 . The results showed that the incidence of IR was significantly higher in the HT-LCMS subgroup than in the NT-LCMS subgroup when IR was defined by HIN (61.50% vs 18.62%, P < 0.001), increased HOMA-IR (72.19% vs 42.76%, P < 0.001), and IFG (24.06% vs 7.59%, P < 0.001; Figure 3A ), whereas the CLIA platform could not discern differences in IR between women with HT and NT ( Figure 3B ).
| OGTT dynamic glucose and insulin curves for HT and non-HT PCOS patients
The results of the 75-g OGTT for PCOS women revealed significantly elevated levels of relevant IR parameters (GLU-0h, GLU-2h,
INS-0h, INS-1h, and INS-2h) in the HT-LCMS subgroup compared
to those in the NT-LCMS subgroup, as shown below: GLU-2h Figure 4A ,B). Again, no statistically significant difference was found between women with CLIA-based HT and NT according to the dynamic glucose ( Figure 4C ) and insulin ( Figure 4D ) curves.
| Predictive ability of IR for HA by ROC curves
ROC curves were plotted to predict HA using IR-associated param- Table 1) .
| D ISCUSS I ON
As LC-MS/MS enables TT measurement with high accuracy, we compared LC-MS/MS and CLIA measurements of TT levels of the subjects in the present study, aiming to reassess the potential correlation between HA and IR Based on the LC-MS/MS measurements, an HA incidence of up to 80.99% was observed in patients with IR in the PCOS population, which was significantly higher than that in the women without IR, and vice versa, a higher IR rate (61.50%)
was found in those women with increased TT levels compared with that in women with normal TT levels. Therefore, we speculate that IR is not considered one of the diagnostic criteria for PCOS in the Rotterdam consensus because of the less accurate methods previously used to measure androgens and that these methods might have been unable to detect a correlation between IR and HA/PCOS.
In the present study, we first compared TT levels measured by LC-MS/MS and CLIA between the non-PCOS IR cohort and the control group. As expected, the mean TT level measured by LC-MS/MS was significantly higher in the IR cohort than in the control group (Figure 1 ). Among the patients with PCOS, the incidence of HA was also observed to be much higher in the IR subgroup than in the non-IR subgroup when increased fasting insulin (80.97% vs 37.89%, P < 0.001), increased HOMA-IR (68.53% vs 38.52%, P < 0.001), and IFG (80.36% vs 51.45%, P < 0.001) were used to define IR In contrast, such a notable difference in the incidence of HA was not seen between the CLIA-based IR and non-IR subgroups.
On the other hand, a higher IR rate was also found in the HT 
4,15
Our study supports the idea that IR or compensatory HIN is associated with the occurrence or progression of HA among patients with PCOS if, of course, the TT levels can be appropriately measured. This finding was further confirmed by ROC curve analysis and logistic regression analysis, which both indicate a close correlation between IR and a higher risk of HA among PCOS women.
In conclusion, our study revealed a close relationship between HA and IR by LC-MS/MS measurement of TT, which may have been underestimated for a long time due to the lack of an accurate method for quantifying TT. HIN, HOMA-IR, and IFG are likely to contribute to the development of HA from a clinical perspective. In addition to biochemical HA, which is defined by TT levels, IR could also be related to the development of clinical HA, which is identified by mFG score.
